

1. Manuel, I., de San Roman, E. G., Giralt, M. T., Ferrer, I. & Rodriguez-Puertas, R. Type-1 Cannabinoid Receptor Activity During Alzheimer's Disease Progression. *J Alzheimers Dis* (2014).
2. Maroof, N., Ravipati, S., Pardon, M. C., Barrett, D. A. & Kendall, D. A. Reductions in Endocannabinoid Levels and Enhanced Coupling of Cannabinoid Receptors in the Striatum are Accompanied by Cognitive Impairments in the AbetaPPswe/PS1DeltaE9 Mouse Model of Alzheimer's Disease. *J Alzheimers Dis* (2014).
3. van den Elsen, G. A. et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. *Ageing Res Rev* **14**, 56-64 (2014).
4. Cheng, D., Low, J. K., Logge, W., Garner, B. & Karl, T. Chronic cannabidiol treatment improves social and object recognition in double transgenic APP/PS1E9 mice. *Psychopharmacology (Berl)* (2014).
5. Koppel, J. et al. CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. *Mol Med* **20**, 29-36 (2014).
6. Aso, E. & Ferrer, I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. *Front Pharmacol* **5**, 37 (2014).
7. Bedse, G. et al. Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease. *J Alzheimers Dis* (2014).
8. Velayudhan, L. et al. Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review. *Curr Pharm Des* (2013).
9. Fagan, S. G. & Campbell, V. A. The Influence of Cannabinoids on Generic Traits of Neurodegeneration. *Br J Pharmacol* (2013).
10. Di Iorio, G. et al. The endocannabinoid system: a putative role in neurodegenerative diseases. *Int J High Risk Behav Addict* **2**, 100-106 (2013).
11. Casarejos, M. J. et al. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. *J Alzheimers Dis* **35**, 525-539 (2013).
12. Maroof, N., Pardon, M. C. & Kendall, D. A. Endocannabinoid signalling in Alzheimer's disease. *Biochem Soc Trans* **41**, 1583-1587 (2013).
13. D'Addario, C. et al. Endocannabinoid signaling in Alzheimers disease: current knowledge and future directions. *J Biol Regul Homeost Agents* **27**, 61-73 (2013).
14. Koppel, J. et al. CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. *Mol Med* **19**, 357-364 (2013).
15. Rom, S. & Persidsky, Y. Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation. *J Neuroimmune Pharmacol* (2013).
16. Scuderi, C., Steardo, L. & Esposito, G. Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y Cells Through PPARgamma Involvement. *Phytother Res* (2013).
17. da Silva, V. K. et al. Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNMI1 Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection. *Mol Neurobiol* (2013).
18. Caramia, G. [Essential fatty acids and lipid mediators. Endocannabinoids]. *Pediatr*

- Med Chir* **34**, 65-72 (2012).
19. Karl, T., Cheng, D., Garner, B. & Arnold, J. C. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. *Expert Opin Ther Targets* **16**, 407-420 (2012).
 20. Chen, Y. et al. Nicotine-Induced Neuroprotection Against Ischemic Injury Involves Activation of Endocannabinoid System in Rats. *Neurochem Res* (2012).
 21. Chen, R. et al. Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease. *Cell Rep* (2012).
 22. Sanchez-Blazquez, P., Rodriguez-Munoz, M., Bailon, C. & Garzon, J. GPCRs promote the release of zinc ions mediated by nNOS/NO and the Redox transducer RGSZ2 protein. *Antioxid Redox Signal* (2012).
 23. D'Addario, C. et al. Epigenetic regulation of Fatty Acid amide hydrolase in Alzheimer disease. *PLoS One* **7**, e39186 (2012).
 24. Harvey, B. S., Ohlsson, K. S., Maag, J. L., Musgrave, I. F. & Smid, S. D. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. *Neurotoxicology* (2012).
 25. Benito, C. et al. Beta Amyloid Exacerbates Inflammation in Astrocytes Lacking Fatty Acid Amide Hydrolase through a Mechanism Involving Ppar-alpha, Ppar-gamma and Trpv1, But Not Cb(1) or Cb(2) Receptors. *Br J Pharmacol* (2012).
 26. Piro, J. R. et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. *Cell Rep* **1**, 617-623 (2012).
 27. Howes, M. J. & Perry, E. The role of phytochemicals in the treatment and prevention of dementia. *Drugs Aging* **28**, 439-468 (2011).
 28. Mulder, J. et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. *Brain* **134**, 1041-1060 (2011).
 29. Chen, X., Zhang, J. & Chen, C. Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. *Neuroscience* **178**, 159-168 (2011).
 30. Harris, H. & Rubinsztein, D. C. Control of autophagy as a therapy for neurodegenerative disease. *Nat Rev Neurol* (2011).
 31. Esposito, G. et al. Cannabidiol Reduces Abeta-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARgamma Involvement. *PLoS One* **6**, e28668 (2011).
 32. Martin-Moreno, A. M. et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers' disease. *Mol Pharmacol* (2011).
 33. Romani, R. et al. Anandamide and its congeners inhibit human plasma butyrylcholinesterase. Possible new roles for these endocannabinoids? *Biochimie* (2011).
 34. Jung, K. M. et al. An amyloid beta(42)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. *Neurobiol Aging* (2011).
 35. Gowran, A., Noonan, J. & Campbell, V. A. The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration. *CNS Neurosci Ther* (2010).
 36. Rivers, J. R. & Ashton, J. C. The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies. *Cent Nerv Syst Agents Med*

- Chem* **10**, 47-64 (2010).
37. Mishra, S., Mishra, M., Seth, P. & Sharma, S. K. Tetrahydrocurcumin confers protection against amyloid beta-induced toxicity. *Neuroreport* (2010).
 38. Fowler, C. J., Rojo, M. L. & Rodriguez-Gaztelumendi, A. Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity? *Exp Neurol* (2010).
 39. Lee, J. H. et al. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. *Neurochem Int* (2010).
 40. Noonan, J. et al. Endocannabinoids prevent {beta}-amyloid-mediated lysosomal destabilisation in cultured neurones. *J Biol Chem* (2010).
 41. Kalifa, S., Polston, E. K., Allard, J. S. & Manaye, K. F. Distribution Patterns of Cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(DeltaE9) double transgenic mice. *Brain Res* (2010).
 42. Bisogno, T. & Di Marzo, V. Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders. *CNS Neurol Disord Drug Targets* (2010).
 43. Orgado, J. M., Fernandez-Ruiz, J. & Romero, J. The endocannabinoid system in neuropathological states. *Int Rev Psychiatry* **21**, 172-180 (2009).
 44. Tolon, R. M. et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. *Brain Res* (2009).
 45. Sarkar, S., Ravikumar, B., Floto, R. A. & Rubinsztein, D. C. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. *Cell Death Differ* **16**, 46-56 (2009).
 46. Hwang, J. et al. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. *Life Sci* (2009).
 47. Koppel, J. et al. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. *Lipids Health Dis* **8**, 2 (2009).
 48. Basavarajappa, B. S., Nixon, R. A. & Arancio, O. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. *Mini Rev Med Chem* **9**, 448-462 (2009).
 49. Chen, B. et al. Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimer's Disease Mouse Model. *Curr Alzheimer Res* (2009).
 50. Romero, J. & Orgado, J. M. Cannabinoids and Neurodegenerative Diseases. *CNS Neurol Disord Drug Targets* (2009).
 51. Bisogno, T. & Di Marzo, V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. *Curr Pharm Des* **14**, 2299-3305 (2008).
 52. Buznikov, G. A. et al. Sea urchin embryonic development provides a model for evaluating therapies against beta-amyloid toxicity. *Brain Res Bull* **75**, 94-100 (2008).
 53. Fernandez-Ruiz, J., Pazos, M. R., Garcia-Arencibia, M., Sagredo, O. & Ramos, J. A. Role of CB(2) receptors in neuroprotective effects of cannabinoids. *Mol Cell Endocrinol* (2008).
 54. Nunez, E. et al. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. *Neuroscience* **151**, 104-110 (2008).

55. de Ceballos, M. L. Endocannabinoids in Alzheimer's Disease. *Cannabinoids and the Brain* (2008).
56. Yang, H. & Chen, C. Cyclooxygenase-2 in Synaptic Signaling. *Curr Pharm Des* **14**, 1443-1451 (2008).
57. Cabral, G. A. & Griffin-Thomas, L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. *Endocr Metab Immune Disord Drug Targets* **8**, 159-172 (2008).
58. Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Rev Bras Psiquiatr* **30**, 271-280 (2008).
59. Buznikov, G. A. et al. Amyloid Precursor Protein 96-110 and Beta-amyloid 1-42 Elicit Developmental Anomalies in Sea Urchin Embryos and Larvae That Are Alleviated By Neurotransmitter Analogs for Acetylcholine, Serotonin and Cannabinoids. *Neurotoxicol Teratol* (2008).
60. Komorowski, J. & Stepien, H. [The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans.]. *Postepy Hig Med Dosw (Online) M* **61**, 99-105 (2007).
61. Klein, T. W. & Newton, C. A. Therapeutic potential of cannabinoid-based drugs. *Adv Exp Med Biol* **601**, 395-413 (2007).
62. Benito, C., Nunez, E., Pazos, M. R., Tolon, R. M. & Romero, J. The endocannabinoid system and Alzheimer's disease. *Mol Neurobiol* **36**, 75-81 (2007).
63. Maccarrone, M., Battista, N. & Centonze, D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. *Prog Neurobiol* **81**, 349-379 (2007).
64. Micale, V., Mazzola, C. & Drago, F. Endocannabinoids and neurodegenerative diseases. *Pharmacol Res* **56**, 382-392 (2007).
65. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. *Dialogues Clin Neurosci* **9**, 413-430 (2007).
66. Esposito, G. et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. *Br J Pharmacol* **151**, 1272-1279 (2007).
67. Campbell, V. A. & Gowran, A. Alzheimer's disease; taking the edge off with cannabinoids? *Br J Pharmacol* (2007).
68. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A. & Iuvone, T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. *J Mol Med* **84**, 253-258 (2006).
69. Walther, S., Mahlberg, R., Eichmann, U. & Kunz, D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. *Psychopharmacology (Berl)* **185**, 524-528 (2006).
70. Velez-Pardo, C. & Del Rio, M. J. Avoidance of A β [(25-35)] / (H₂O)₂ - induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWH-015 via receptor-independent and PI3K-dependent mechanisms: role of NF-kappaB and p53. *Med Chem* **2**, 471-479 (2006).
71. Curtis, M. A., Faull, R. L. & Glass, M. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. *J Chem Neuroanat* **31**, 210-215 (2006).

72. Eubanks, L. M. et al. A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology. *Mol Pharm S* **3**, 773-777 (2006).
73. Ehrhart, J. et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. *J Neuroinflammation* **2**, 29 (2005).
74. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci* **25**, 1904-1913 (2005).
75. Milton, N. G. Phosphorylated amyloid-beta: the toxic intermediate in Alzheimer's disease neurodegeneration. *Subcell Biochem* **38**, 381-402 (2005).
76. Puffenberger, R. A. Molecular biology of the enzymes that degrade endocannabinoids. *Curr Drug Targets CNS Neurol Disord* **4**, 625-631 (2005).
77. Fernandez-Ruiz, J. & Gonzales, S. Cannabinoid control of motor function at the basal ganglia. *Handb Exp Pharmacol* 479-507 (2005).
78. Reefer Rx: marijuana as medicine. The legal status of smoking marijuana for medical purposes is cloudy, but could compounds related to it be used to treat Alzheimer's disease, obesity, or pain? *Harv Health Lett* **29**, 6-7 (2004).
79. Iuvone, T. et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from *Cannabis sativa*, on beta-amyloid-induced toxicity in PC12 cells. *J Neurochem* **89**, 134-141 (2004).
80. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. *Schmerz* **18**, 197-202 (2004).
81. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. *Prostaglandins Leukot Essent Fatty Acids* **66**, 257-267 (2002).
82. Milton, N. G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. *Neurosci Lett* **332**, 127-130 (2002).
83. Milton, N. G. Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer's amyloid-beta peptide. *Neurotoxicology* **22**, 767-774 (2001).
84. Ryback, R. Bioelectrical modulators and the cell membrane in psychiatric medicine. *Psychopharmacol Bull* **35**, 5-44 (2001).
85. Lagalwar, S., Bordayo, E. Z., Hoffmann, K. L., Fawcett, J. R. & Frey, W. H. Anandamides inhibit binding to the muscarinic acetylcholine receptor. *J Mol Neurosci* **13**, 55-61 (1999).
86. Gadzicki, D., Muller-Vahl, K. & Stuhmann, M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. *Mol Cell Probes* **13**, 321-323 (1999).
87. Volicer, L. Tube feeding in Alzheimer's disease is avoidable. *J Nutr Health Aging* **2**, 122-123 (1998).
88. Dronabinol in Alzheimer's disease. *Harv Ment Health Lett* **15**, 7 (1998).
89. Volicer, L., Stelly, M., Morris, J., McLaughlin, J. & Volicer, B. J. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* **12**, 913-919 (1997).
90. Westlake, T. M., Howlett, A. C., Bonner, T. I., Matsuda, L. A. & Herkenham, M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of

normal aged and Alzheimer's brains. *Neuroscience* **63**, 637-652 (1994).

91. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). *Drugs* **43**, 295-315 (1992).